Latest AIM Breakfast

AIM Breakfasts

AIM BREAKFAST – 13th December 2017

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 951

Total number of AIM Companies trading: 909*
* As at 11 December 2017

Dish of the Day:

Re-introduction of Range Resources (RRL) to AIM.  Now completed acquisition of Range Resources Drilling. Mkt Cap £17.4m.

Off the Menu:

No Leavers Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 86*

Total number of ISDX Growth Market Companies trading: 83*
* As at 11 December 2017

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?


Fusion Antibodies— Sch1 from the Belfast based contract research organisation providing services to biopharmaceutical and diagnostics companies that are involved in the development of antibodies for both therapeutic drug and diagnostic applications. Offer to raise £5.5m for the Company and £1.075m for selling shareholders at 82p with market cap of £18.1m. Due 18 Dec

Erris Resources PLC—a mineral exploration and development company currently focused on two geographic areas. Offer TBC, expected 21 December 2017

CIP Merchant Capital—Closed ended investment Company. Sector focus oil & gas, healthcare, pharma, and real estate. Offer TBA. Due 21 Dec

Panthera Resources— The Company was established to act as a holding company for Indo Gold Limited, an unlisted Australian registered company. The Company aims to explore and develop gold assets in India and West Africa. Offer TBC, expected 20 Dec

Sumo Group—one of the UK’s largest independent developers of AAA-rated video games providing both turnkey and co-development solutions, including initial concept and pre-production. Offer TBC. Due late Dec

Pelatro—provider of proprietary software solutions to enterprise-level customers for various aspects of precision marketing for use in B2C applications. Offer TBC, expected 19 December 2017

Fusion Antibodies—contract research organisation providing services to biopharmaceutical and diagnostics companies that are involved in the development of antibodies for both therapeutic drug and diagnostic applications.  Raising £5.5m at 82p plus £1.075mn vendor sale. £mkt cap £18.1m Due 18 Dec.

Sirius Petroleum—RTO. Becoming an operating company in the Ororo Field in Nigeria. Raising £7.2m/ Mkt Cap £35.6m.  Due 19 Dec.

Bushveld Minerals—RTO of Bushveld Vametco and therefore 78.8% of Strategic Minerals Corporation, the intermediate holding company that owns a 75 per cent. interest in the Vametco Vanadium Mine.

Eqtec—Company with access to a proprietary advanced gasification technology used in industrial size power plants to convert waste into synthetic gas to generate electricity.  Raising £1.6m. Mkt Cap £8.7m. Due 21 Dec.

Volex VLX.L—The global provider of cable assemblies is proposing to move from the main market to AIM on 19 January. £71m market cap. FYMar18E rev £241.5m and £7.19m PBT

Miriad Advertising—Global video advertising company incorporated in 2015 and is engaged in the development of native in-video advertising. 2016 rev £0.7m and £7.3m operating loss. Offer TBA. Expected 19 Dec.

OnTheMarket—Intention to float on AIM to raise c.£50m which will be used to fund the growth of the portal, already the third biggest UK residential property portal provider. Expected valuation £200m to £250m.

Main Market Specialist Fund Segment

Sure Ventures –Raising  up to £50m at £1. Focus on FinTech, IoT and Augmented/Virtual Reality. Due 22 Dec.

Tufton Oceanic Assets  –  intends to invest in a diversified portfolio of secondhand commercial sea-going vessels . Aiming to raise over $100m. Due 20 Dec

Main Market Standard Listing

Shefa Yamin minerals company focused on the exploration for precious stones in Northern Israel. Net Proceeds will be used to advance the Company’s mining project. Due 18 Dec.

Main Market Premium Listing

GEMS Education—report by Reuters that the private schools group is seeking a $4.5bn to $5bn London float in 2018. FYAug17 rev $926.2m and adjusted EBITDA $261.6m.

Greensphere Capital –$500m raise.  Aims to provide Shareholders with an attractive yield from a portfolio of sustainable infrastructure assets diversified by geographies and sectors and to realise long-term growth  capital value.  Due 20 Dec

Vivo Energy—The Africa-focused company, which operates around 1,800 Shell forecourts across 16 countries  reported by City A.M. to be preparing for a London float next year

Aberdeen Standard European Logistics Income—Investment Trust targeting £250m raise. Investing in a high quality portfolio of European logistics assets. Due 15 Dec.

Aviva Investors Secure Income REIT  IPO PULLED – Targeting £200m raise. Will invest in a diversified portfolio of high quality, long-lease commercial real estate assets located within the UK and leased to predominantly investment grade tenants. Due 15 Dec.


Breakfast Buffet

Forbidden Update (FBT.L) 4.63p £8.35m

Shareholder Update on new priorities. Strategy to revolve around the Company’s core patented technology Blackbird™. To engage further with existing customers, new Proofs of Concept planned and most of sales and marketing team to be replaced.  “As a result of the significant management changes this year, and the longer infrastructure sale cycle, the financial results for the year ending 31 December 2017 will be below last year.

However, as noted above, in the past few months the Company has signed a number of exciting new PoCs in multiple regions and new sectors. This means that the Company now has the most PoCs it has ever had at any one time.” We could see no forecasts.


Vernalis (VER.L) 12.87p £67.78m

Vernalis  has entered into a drug discovery collaboration with Daiichi Sankyo Company, Limited utilizing Vernalis’ fragment and structure-based drug discovery platform against undisclosed oncology targets. The financial terms of this collaboration are not disclosed.

“We are delighted to be working with Daiichi Sankyo on this project. This is another excellent endorsement of our market leading fragment and structure-based drug discovery platform and we look forward to a successful collaboration with Daiichi Sankyo.”


Ortac Resources (OTC.L) 2.62p £6.14m

Ortac Resources Ltd is pleased to announce that in relation to the offer for the balance of the issued share capital of Casa Mining Ltd (“Casa”) (the “Offer”), it has increased its interest in Casa from approximately 45% to 84.7% since the Offer was announced on 10 November 2017.

If the Offer is accepted by all shareholders of Casa, then a total of approximately 100,000,000 new ordinary shares of no par value of the Company (“New Ordinary Shares”) will be issued to Casa shareholders pursuant to the Offer and acquisition of Casa.”


Mereo BioPharma (MPH.L) 327p £237.9m

Update on its clinical development pipeline in and a general corporate update. Reported positive top-line data from BCT-197 (acute exacerbations of chronic obstructive pulmonary disease) Phase 2 study, with primary endpoint met; Completed enrolment of BGS-649 (Hypogonadotropic Hypogonadism in obese men) Phase 2b study and on track to deliver top-line data in Q1 2018;   BPS-804 (osteogenesis imperfecta) granted EMA PRIME designation; AZD-9668 (alpha-1 antitrypsin deficiency) licensed from AstraZeneca, transition progressing according to plan and Phase 2 study expected to start in 2018. Cash and deposits £46.8m at 30 Nov.


Ubisense Group (UBI.L) 45.5p £33.25m

The specialist in “in enterprise location intelligence solutions, is today announcing a new contract in the space and satellites sector, the first deployment in this sector for its SmartSpace platform and associated products. The customer is one of the world’s leading manufacturers of commercial and military geosynchronous satellite platforms and space probes.

Ubisense’s software platform and location system will support the customer’s strategy to double production output. By integrating location technologies into a single operational view of real-time production, SmartSpace provides complete visibility of the manufacturing process, creating efficiencies across operations and enabling significant growth in production.” We could see no forecasts.


Prairie Mining (PDZ.L) 29.62p £49.62m

Notes market fundamentals continue to improve for Prairie’s two large-scale Tier One coking coal projects as the European Commission reaffirms coking coal as a “Critical Raw Material” for Europe. “The outlook for increased coking coal demand from Europe’s steel producers coupled with reducing European supply is creating a ‘perfect storm’ for Prairie to become the go-to supplier of the critical raw material. Europe’s steel producers which supply the vast automobile industry are now noting the potential increase in demand for steel due to the move towards vehicle electrification over the coming decades. We are well positioned to supply the required coking coal to produce the steel from the heart of Europe’s steel making industry.”



The Company reaffirms it’s plan to dual-list on AIM and the NEX Exchange Growth Market. AIM admission and NEX Exchange Growth Market re-admission is expected in Q1 2018, and remains conditional on raising the pre-requisite funding requirements.

 CPR highlights significant reserves and gross contingent resources of 73          Million Barrels of Oil and 626 BCF of Gas on Georgian assets.

Includes gross 2P oil reserves of 1.6 MMbbl and an NPV10 of $26.9m for its Norio licence.


Bacanora Minerals (BCN.L) 95p £126.15m

“Bacanora Minerals Ltd., the London and Canadian listed lithium company, is pleased to announce that the results of the Feasibility Study (‘FS’) for the Sonora Lithium Project1 in Mexico (‘Sonora’ or ‘the Project’) confirm the positive economics and favourable operating costs of a 35,000 tonnes per annum (‘tpa’) battery grade Li2CO3 operation.  


The FS estimates a pretax project Net Present Value (‘NPV’) of US$1.253 billion at an 8% discount rate and an Internal Rate of Return (‘IRR’) of 26.1%, and Life of Mine (‘LOM’) operating costs of $3,910/t of lithium carbonate (‘Li2CO3’). “


Microsaic Systems (MSYS.L) 1.8p £3.26m

“The developer of chip-based mass spectrometry instruments, announces that it has signed a research agreement extending its collaboration with a long standing global partner in the scale up and manufacture of biopharmaceutical drugs. This amendment to the agreement has been entered into following the successful completion of a collaboration stage contracted in a previous amendment announced on 7 April 2017.” We could see no forecasts.


REACT Group (REAT.L) 0.35p £0.96m

Trading update.  The Board now expects that the pre-tax loss for the year ended 30 September 2017 will be around £0.475m (versus around £0.4m as previously expected). 

The reason for this changed expectation is primarily due to a non-cash adjustment relating to an amortisation of REACT’s client list made on acquisition of c£44k, and c£22k of costs relating to the now closed EPUK business.

Trading in the current financial year starting 1 October 2017 has made an encouraging start. Whilst (unaudited) management accounts for October show a smaller monthly loss, the November figures indicate break-even for the month.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email with “unsubscribe me”.